RUBICON ORGANICS INC (ROMJ.CA) Stock Fundamental Analysis
Canada - TSX-V:ROMJ - CA78112W1005 - Common Stock
0.49 CAD
+0.01 (+2.08%)
Overall ROMJ gets a fundamental rating of 6 out of 10. We evaluated ROMJ against 31 industry peers in the Pharmaceuticals industry. ROMJ has only an average score on both its financial health and profitability. ROMJ is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make ROMJ suitable for growth investing!
1. Profitability
1.1 Basic Checks
ROMJ had negative earnings in the past year.
In the past year ROMJ had a positive cash flow from operations.
In the past 5 years ROMJ always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: ROMJ reported negative operating cash flow in multiple years.
1.2 Ratios
ROMJ's Return On Assets of 0.38% is fine compared to the rest of the industry. ROMJ outperforms 67.74% of its industry peers.
ROMJ has a better Return On Equity (0.55%) than 67.74% of its industry peers.
ROMJ's Return On Invested Capital of 21.14% is amongst the best of the industry. ROMJ outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ROMJ is significantly above the industry average of 7.77%.
The last Return On Invested Capital (21.14%) for ROMJ is above the 3 year average (19.33%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.38% | ||
| ROE | 0.55% | ||
| ROIC | 21.14% |
ROA(3y)-4.91%
ROA(5y)-14.11%
ROE(3y)-7.24%
ROE(5y)-22.2%
ROIC(3y)19.33%
ROIC(5y)N/A
1.3 Margins
ROMJ has a better Profit Margin (0.43%) than 67.74% of its industry peers.
Looking at the Operating Margin, with a value of 27.18%, ROMJ belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
With an excellent Gross Margin value of 59.50%, ROMJ belongs to the best of the industry, outperforming 87.10% of the companies in the same industry.
In the last couple of years the Gross Margin of ROMJ has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.18% | ||
| PM (TTM) | 0.43% | ||
| GM | 59.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ROMJ is creating value.
Compared to 1 year ago, ROMJ has more shares outstanding
ROMJ has more shares outstanding than it did 5 years ago.
ROMJ has a better debt/assets ratio than last year.
2.2 Solvency
ROMJ has an Altman-Z score of 1.56. This is a bad value and indicates that ROMJ is not financially healthy and even has some risk of bankruptcy.
ROMJ's Altman-Z score of 1.56 is amongst the best of the industry. ROMJ outperforms 83.87% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that ROMJ is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.19, ROMJ is in line with its industry, outperforming 54.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.56 |
ROIC/WACC2.42
WACC8.74%
2.3 Liquidity
A Current Ratio of 2.92 indicates that ROMJ has no problem at all paying its short term obligations.
With an excellent Current ratio value of 2.92, ROMJ belongs to the best of the industry, outperforming 80.65% of the companies in the same industry.
ROMJ has a Quick Ratio of 1.46. This is a normal value and indicates that ROMJ is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.46, ROMJ perfoms like the industry average, outperforming 58.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.92 | ||
| Quick Ratio | 1.46 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 104.07% over the past year.
ROMJ shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.19%.
ROMJ shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.14% yearly.
EPS 1Y (TTM)104.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%246.25%
Revenue 1Y (TTM)34.19%
Revenue growth 3Y29.14%
Revenue growth 5YN/A
Sales Q2Q%23.78%
3.2 Future
ROMJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 91.29% yearly.
ROMJ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.51% yearly.
EPS Next Y125%
EPS Next 2Y100%
EPS Next 3Y91.29%
EPS Next 5YN/A
Revenue Next Year21.85%
Revenue Next 2Y23.01%
Revenue Next 3Y28.51%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Forward Earnings ratio is 6.06, which indicates a rather cheap valuation of ROMJ.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ROMJ indicates a rather cheap valuation: ROMJ is cheaper than 93.55% of the companies listed in the same industry.
ROMJ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 32.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.06 |
4.2 Price Multiples
ROMJ's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ROMJ is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.93 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ROMJ may justify a higher PE ratio.
A more expensive valuation may be justified as ROMJ's earnings are expected to grow with 91.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y100%
EPS Next 3Y91.29%
5. Dividend
5.1 Amount
No dividends for ROMJ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:ROMJ (11/7/2025, 7:00:00 PM)
0.49
+0.01 (+2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.22%
Inst Owner ChangeN/A
Ins Owners42.42%
Ins Owner ChangeN/A
Market Cap32.92M
Revenue(TTM)55.06M
Net Income(TTM)235.20K
Analysts82.86
Price Target1.17 (138.78%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.54%
PT rev (3m)4.55%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)150%
EPS NY rev (1m)N/A
EPS NY rev (3m)114.29%
Revenue NQ rev (1m)-1.27%
Revenue NQ rev (3m)12.72%
Revenue NY rev (1m)-0.79%
Revenue NY rev (3m)10.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.06 | ||
| P/S | 0.6 | ||
| P/FCF | N/A | ||
| P/OCF | 10.89 | ||
| P/B | 0.77 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | 1.93 |
EPS(TTM)0
EYN/A
EPS(NY)0.08
Fwd EY16.49%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.04
OCFY9.18%
SpS0.82
BVpS0.64
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.38% | ||
| ROE | 0.55% | ||
| ROCE | 29.36% | ||
| ROIC | 21.14% | ||
| ROICexc | 24.66% | ||
| ROICexgc | 26.08% | ||
| OM | 27.18% | ||
| PM (TTM) | 0.43% | ||
| GM | 59.5% | ||
| FCFM | N/A |
ROA(3y)-4.91%
ROA(5y)-14.11%
ROE(3y)-7.24%
ROE(5y)-22.2%
ROIC(3y)19.33%
ROIC(5y)N/A
ROICexc(3y)24.75%
ROICexc(5y)N/A
ROICexgc(3y)26.66%
ROICexgc(5y)N/A
ROCE(3y)26.85%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5YN/A
F-Score7
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 204.1% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 13.51 | ||
| Cash Conversion | 16.58% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.92 | ||
| Quick Ratio | 1.46 | ||
| Altman-Z | 1.56 |
F-Score7
WACC8.74%
ROIC/WACC2.42
Cap/Depr(3y)93.56%
Cap/Depr(5y)171.69%
Cap/Sales(3y)7.51%
Cap/Sales(5y)22.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)104.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%246.25%
EPS Next Y125%
EPS Next 2Y100%
EPS Next 3Y91.29%
EPS Next 5YN/A
Revenue 1Y (TTM)34.19%
Revenue growth 3Y29.14%
Revenue growth 5YN/A
Sales Q2Q%23.78%
Revenue Next Year21.85%
Revenue Next 2Y23.01%
Revenue Next 3Y28.51%
Revenue Next 5YN/A
EBIT growth 1Y59.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.19%
EBIT Next 3Y4.44%
EBIT Next 5YN/A
FCF growth 1Y-210.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.26%
OCF growth 3YN/A
OCF growth 5YN/A
RUBICON ORGANICS INC / ROMJ.CA FAQ
What is the fundamental rating for ROMJ stock?
ChartMill assigns a fundamental rating of 6 / 10 to ROMJ.CA.
What is the valuation status for ROMJ stock?
ChartMill assigns a valuation rating of 6 / 10 to RUBICON ORGANICS INC (ROMJ.CA). This can be considered as Fairly Valued.
What is the profitability of ROMJ stock?
RUBICON ORGANICS INC (ROMJ.CA) has a profitability rating of 6 / 10.